Giant-cell carcinoma of the lung
|Giant cell carcinoma of the lung|
|Classification and external resources|
Giant-cell carcinoma of the lung (GCCL) is a rare histological form of large-cell lung carcinoma, a subtype of undifferentiated lung cancer, traditionally classified within the non-small-cell lung carcinomas (NSCLC).
The characteristic feature of this highly lethal malignancy is the distinctive light microscopic appearance of its extremely large cells, which are bizarre and highly pleomorphic, and which often contain more than one huge, misshapen, pleomorphic nucleus ("syncytia"), which result from cell fusion.
Although it is common in the lung cancer literature to refer to histologically mixed tumors containing significant numbers of malignant giant cells as "giant-cell carcinomas", technically a diagnosis of "giant-cell carcinoma" should be limited strictly to neoplasms containing only malignant giant cells (i.e. "pure" giant-cell carcinoma).
Aside from the great heterogeneity seen in lung cancers (especially those occurring among tobacco smokers), the considerable variability in diagnostic and sampling techniques used in medical practice, the high relative proportion of individuals with suspected GCCL who do not undergo complete surgical resection, and the near-universal lack of complete sectioning and pathological examination of resected tumor specimens prevent high levels of quantitative accuracy.
- 1 Epidemiology
- 2 Classification
- 3 Microscopic features and cytology
- 4 Tissue architectural features
- 5 Macroscopic features
- 6 Staining and immunohistochemistry
- 7 Differential diagnosis
- 8 Sites of metastasis
- 9 Pathogenesis and genetics
- 10 Combined/multiphasic tumors containing giant cells
- 11 Imaging characteristics
- 12 Positron emission tomography scanning
- 13 Metabolic pathways
- 14 Paraneoplastic syndromes
- 15 Treatment
- 16 Prognosis
- 17 History
- 18 References
- 19 External links
The true incidence, prevalence, and mortality of GCCL is generally unknown due to a lack of accurate cancer data on a national level. It is known to be a very rare tumor variant in all populations examined, however. In an American study of a database of over 60,000 lung cancers, GCCL comprised between 0.3% and 0.4% of primary pulmonary malignancies, with an age-adjusted incidence rate of about 3 new cases per million persons per year. With approximately 220,000 total lung cancers diagnosed in the US each year, the proportion suggests that approximately 660 and 880 new cases are diagnosed in Americans annually.
However, in a more recent series of 4,212 consecutive lung cancer cases, only one (0.024%) lesion was determined to be a "pure" giant-cell carcinoma after complete sectioning of all available tumor tissue. While some evidence suggests GCCL may have been considerably more common several decades ago, with one series identifying 3.4% of all lung carcinomas as giant-cell malignancies, it is possible that this number reflect
Most published case series and reports on giant cell-containing lung cancers show that they are diagnosed much more frequently in men than they are in women, with some studies showing extremely high male-to-female ratios (12:1 or more). In a study of over 150,000 lung cancer victims in the US, however, the gender ratio was just over 2:1, with women actually having a higher relative proportion of giant-cell cancers (0.4%) than men (0.3%).
Giant-cell carcinomas have been reported to be diagnosed in a significantly younger population than all non-small-cell carcinomas considered as a group. Like nearly all lung carcinomas, however, GCCs are exceedingly rare in very young people: in the US SEER program, only 2 cases were recorded to occur in persons younger than 30 years of age between 1983 and 1987. The average age at diagnosis of these tumors has been estimated at 60 years.
The vast majority of individuals with GCCL are heavy smokers.
Although the definitions of "central" and "peripheral" can vary between studies, GCCL are consistently diagnosed much more frequently in the lung periphery. In a review of literature compiled by Kallenburg and co-workers, less than 30% of GCCLs arose in the hilum or other parts of the "central" pulmonary tree.
A significant predilection for genesis of GCCL in the upper lobes of victims has also been postulated.
For several decades, primary lung cancers were consistently dichotomously classified for treatment and research purposes into small-cell lung carcinomas (SCLCs) and non-small-cell lung carcinomas (NSCLCs), based on an oversimplified approach that is now clearly outmoded. The new paradigm recognizes that lung cancers are a large and extremely heterogeneous family of malignant neoplasms, with over 50 different histological variants included in the 4th (2004) revision of the World Health Organization typing system, the most widely used lung cancer classification scheme ("WHO-2004"). These variants are increasingly appreciated as having different genetic, biological, and clinical properties, including prognoses and responses to treatment regimens, and therefore, that correct and consistent histological classification of lung cancers are necessary to validate and implement optimum management strategies.
About 1% of lung cancers are sarcomas, germ cell tumors, and hematopoietic tumors, while 99% of lung cancers are carcinoma. Carcinomas are tumors composed of transformed, abnormal cells with epithelial tissue architecture and/or molecular characteristics, and which derive from embryonic endoderm. Eight major taxa of lung carcinomas are recognized within the WHO-2004 classification:
- Small-cell carcinoma
- Squamous cell carcinoma
- Large-cell carcinoma
- Adenosquamous carcinoma
- Sarcomatoid carcinoma
- Salivary gland-like carcinoma
The subclassification of GCCL among these major taxa has undergone significant changes in recent decades. Under the 2nd revision (1981) of the WHO classification, it was considered a subtype of large-cell carcinoma. In the 3rd (1999) revision, it was placed within a taxon called "Carcinomas with Pleomorphic, Sarcomatoid, or Sarcomatous Elements", along with pleomorphic carcinoma, spindle cell carcinoma, carcinosarcoma, and pulmonary blastoma, which are (arguably) related variants. While the 4th revision ("WHO-2004") retained the same grouping of lesions as the 3rd revision, the name of the major taxon was shortened to "sarcomatoid carcinomas".
The current rules for classifying lung cancers under WHO-2004, while useful and improved, remain to some extent fairly complex, ambiguous, arbitrary, and incomplete. Although it is fairly common for mixed tumors that are seen to contain malignant giant cells to be called "giant-cell carcinomas", accurate classification of a pulmonary tumor as a GCCL requires that the entire tumor consists only of malignant giant cells. Therefore, complete sampling of the entire tumor — obtained via a surgical resection — is absolutely necessary for a definitive diagnosis of GCCL to be made.
Microscopic features and cytology
The background contained numerous lymphocytes and neutrophils. The shape of the tumor cell was spindle or pleomorphic, and the sizes of the tumor cells varied by more than 5-fold. The tumor cells had an abundant, thick and well-demarcated cytoplasm. The location of the nucleus was centrifugal, and the nucleus was oval or irregularly shaped. Multinucleated giant cells were frequently observed. The size of the nucleus was more than 5 times that of normal lymphocytes, and its size also varied by more than 5-fold. The nuclear membrane was thin, and nuclear chromatin was coarsely granular, while the nucleolus was single and round.
In cytological preparations, giant cells typically appear as single cells or in flat loose clusters, and occasionally in fascicles.
GCCL are considered a member of the most common type of lung cancer, called "non-small-cell carcinomas". This group of lethal neoplasms make up approximately 85% of all lung cancers. By the definition of "large-vs.-small-cell carcinoma", the diameter of GCCL cells must be considerably greater than three times that of a resting (i.e. unstimulated) lymphocyte. Also by definition, GCCL do not contain any amount of these small, neurosecretory granule-containing, neuroendocrine cells that are characteristic of small-cell carcinomas — when they do, the tumor should be classified as a combined small-cell carcinoma.
Compared to most other lung cancer variants, cells comprising GCCL tend to be much larger (up to 150 micrometers diameter, or even larger), Both cells and nuclei show extreme variation in size distribution and shape. Carcinomatous giant cells carcinoma nuclei have been reported to average 5 times the size of lymphocyte nuclei.
The cells from giant-cell carcinomas are anaplastic, and show no evidence of cell maturation or differentiation, lacking the cytological and tissue architectural characteristics of squamous cell carcinoma, adenocarcinoma, neuroendocrine carcinomas, or other more differentiated lung cancer cell types. They tend to be highly pleomorphic (i.e. variable in characteristics), but are most often round and/or polygonal in shape, with a relatively low nuclear-to-cytoplasmic ratio. When associated with spindle cells, as they very frequently are in tumors with mixed histology, malignant giant cells tend to form loosely cohesive aggregate structures on cytological examination. However, when a biopsy sample consists purely of malignant giant cells, the cells tend to be single and disaggregated.
Case series suggest that the relative number of giant cells in a given tumor are generally directly proportional to the size of the tumor, and to the relative amount of necrosis.
Giant cells in a lung cancer are highly associated with the presence of spindle cells.
Subcellular characteristics often noted in the malignant giant cells of GCCL cases include abundant mitochondria, concentric whorls of tonofilament-like fibrils, and aggregates of several pairs of centrioles.
Both "tumor cell-tumor cell" and "leukocyte-tumor cell" emperipolesis (i.e. active penetration of the latter by the former) is very commonly seen in cases of GCCL.
Tissue architectural features
In mixed tumors, giant cells are more likely to be found in higher proportions at the edge of a tumor. When extensive necrosis is present, it is possible for a giant-cell tumor to have only a thin rim of viable cells remaining at the perimeter of the mass.
In one early case series, abundant production of loose malignant giant cells were noted to fill the alveoli of victims without destroying, infiltrating, or disturbing the normal underlying architecture, a pathologic behavior that bears some resemblance to the pneumonic variant of bronchioloalveolar carcinoma.
Extensive tumor necrosis and hemorrhage is extremely common in GCCL.
Although the issue has not been extensively studied in a controlled fashion, GCCLs have been noted to contain significantly elevated levels of VEGF. However, in one study where a giant-cell carcinoma tumor that had been completely excised was sectioned and examined, no qualitative or quantitative abnormalities in tissue vascularization were noted.
GCCL have been noted to be encapsulated, and to be divided via septa into "pseudolobules", by a highly fibrous stroma, suggested to be produced commensurately with tumor growth. The capsule is typically infiltrated with malignant giant cells.
A trend toward less vascularity and tissue density (with lower contrast enhancement on CT) has been noted toward the center of these lesions, especially in larger tumors, and even in tumors without a significant volume of gross necrosis.
Grossly, the cut surfaces of these malignancies are often gray-white or tan, and frequently show myxoid, necrotic, and/or hemorrhagic foci. These sorts of areas often show low levels of contrast enhancement on CT scanning.
Low encapsularity and high levels of tissue collagen tend to be observed, with high contrast enhancement in these areas.
Staining and immunohistochemistry
A case of a brain metastasis from a giant-cell lung carcinoma (both "pure") tested positive for cytokeratins AE1/AE3, and negative for CK-7, CK-20, TTF-1, and GFAP.
Under light microscopy, the giant malignant pleomorphic cells making up a GCCL resemble those found in choriocarcinoma, angiosarcoma, and some forms of true sarcoma, such as malignant fibrous histiocytoma and rhabdomyosarcoma. In some instances, they can also bear considerable resemblance to "activated" histiocytes seen in some inflammatory conditions.
A rare and potentially difficult differential diagnostic dilemma occurs when GCCLs must be separated from pulmonary or mediastinal choriocarcinomas, a critical distinction to me made because while there is a known standard of care for treating choriocarcinoma, as yet there is no generally accepted specific standard treatment for GCCL. Careful review of cell morphology is key to their delineation — while GCCLs show great variation in cell size distributions and morphologies in tumors, choriocarcinomas consistently contain only syncytiotrophoblasts and cytotrophoblasts. GCCL and primary pulmonary choriocarcinoma can also be differentiated on the basis of ultrastructural features by electron microscopy, although EM is not yet widely applicable.
Occasionally, a bone metastasis of a GCCL could potentially be mistaken for a primary giant-cell tumor of bone — interestingly, the latter entity can behave as a neoplasm of benign, frankly malignant, or borderline in its clinical behavior.
Sites of metastasis
GCCLs are particularly notable among lung cancers for their extremely unusual tendency to metastasize to the small intestine, occasionally causing obstruction, severe bleeding, and/or intussusception. This clinical characteristic of GCCL has been seen in cases spanning over half a century in time.
Within the small bowel, the jejunum seems to be a preferred site for metastasis of GCCL.
Brain metastases from GCCL are particularly likely to cause significant cerebral hemorrhages as compared to other lung cancer variants, probably due to greatly increased rates of endothelial proliferation and neovascularization, tumor tissue growth, extensive necrosis, and aggressive local infiltrative character of GCCL cells.
Pathogenesis and genetics
Several studies, both in giant-cell tumor specimens and in cell lines, have identified rearrangement and amplification of the c-myc oncogene, sometimes in combination with mutations of the K-ras gene.
Overexpression of vascular endothelial growth factor (VEGF) has been shown to occur in GCCL and is thought to be related to the high metastatic potential of this lung cancer variant.
Malignant giant cells identical to those found in GCCL commonly occur in lung cancer cases with a prominent major or minor clear-cell carcinoma pattern (for a discussion about this variant, see for example). They have been hypothesized to derive from an undifferentiated multipotent malignant stem cell precursor that is generated in distal bronchioles via an as yet unknown oncogenetic pathway or oncogenetic driver.
Ultrastructurally, malignant giant cells often contain accumulations of microfilaments arranged in whorls near the cell nucleus. These entities appear similar in structure to microfilaments and bundles found in the D1 cell of the gastro-entero-pancreatic endocrine system, and it has been proposed that these D1 cells may be the cancer stem cell for at least some GCCLs. Identically appearing whorled filament structures have also been produced in certain airway cells of animals after treatment with carcinogenic nitrosamines.
Ultrastructural studies have suggested that the malignant giant cells in GCCL are of endodermal lineage.
Remarkably fast growing tumors.
Combined/multiphasic tumors containing giant cells
Malignant giant cells are commonly found — and vary in relative proportion to a greater or lesser degree — in both primary tumors and metastatases of many different variants of lung carcinomas. A number of authors have noted that bizarre malignant giant cells occur more commonly in primary and secondary tumors — including any remaining tumor "deposits" — that have previously been treated with chemotherapy and/or radiation therapy in adjuvant or neoadjuvant protocols.
GCCL often presents as a large peripheral mass that is severely cavitated.
In a number of cases of severe cavitation, the resected tumor remnant consists of only a thin rim of proliferating cells.
Positron emission tomography scanning
On positron emission tomography (PET) scanning, GCCL has been found to have exceedingly high standardized uptake values (SUV) for radioactive glucose, values that are statistically significantly higher than in other histological variants of lung cancer.
GCCL have been long known for secretion of the beta subunit of human chorionic gonadotropin (beta-HCG), often in large amounts, which can lead to very high levels of estrogen and painful gynecomastia (breast enlargement) in males as paraneoplastic signs.
GCCL has also been reported to produce plasminogen activator as a paraneoplastic phenomenon.
Because of its rarity, there have been no randomized clinical trials of treatment of GCCL, and all information available derives from small retrospective institutional series or multicenter metadata.
Many small series have suggested that the prognosis of lung tumors with giant cells is worse than that of most other forms of non-small-cell lung cancer (NSCLC), including squamous cell carcinoma, and spindle cell carcinoma.
The overall five-year survival rate in GCCL varies between studies but is generally considered to be very low. The (US) Armed Forces Institute of Pathology has reported a figure of 10%, and in a study examining over 150,000 lung cancer cases, a figure of 11.8% was given. However, in the latter report the 11.8% figure was based on data that included spindle cell carcinoma, a variant which is generally considered to have a less dismal prognosis than GCCL. Therefore, the likely survival of "pure" GCCL is probably lower than the stated figure.
In the large 1995 database review by Travis and colleagues, giant-cell carcinoma has the third-worst prognosis among 18 histological forms of lung cancer. (Only small-cell carcinoma and large-cell carcinoma had shorter average survival.)
Most GCCL have already grown and invaded locally and/or regionally, and/or have already metastasized distantly, and are inoperable, at the time of diagnosis.
Most sources credit Nash and Stout with publishing the first detailed report in the medical literature recognizing GCCL as a distinct clinicopathological entity in 1958. However, there is some evidence that suggests this tumor phenotype was described as early as 1951. In a report on 3 cases of giant-cell lung carcinoma published in 1961 by Z.M. Naib, the author cites 2 previous studies related to GCCL — one published in 1951 by M.M. Patton and co-workers, and one published in 1955 by Walton and Pryce. In 1969, Dr. Alexander Kennedy, in a case series of 3 GCCL Kennedy published in 1969, credited Hadley and Bullock with the first usage of the term "giant-cell carcinoma" 16 years prior.
GCCL was first confirmed as an epithelial tumor (and not a dedifferentiated pleomorphic sarcoma) in 1961. In 1964–65, theories were postulated that GCCLs were dediffentiated adenocarcinomas and, in some cases, were thought to derive from clear-cell adenocarcinomas.
- Travis, William D; Brambilla, Elisabeth; Muller-Hermelink, H Konrad; et al., eds. (2004). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (PDF). World Health Organization Classification of Tumours. Lyon: IARC Press. ISBN 92-832-2418-3. Retrieved 27 March 2010.
- Travis WD, Travis LB, DeVesa SS (1995). "Lung Cancer". Cancer. 75: 191–202. doi:10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y. PMID 8000996.
- "Fact Sheet: Cancer of the Lung and Bronchus". National Cancer Institute, SEER Program. Retrieved February 24, 2012.
- Martin LW, Correa AM, Ordonez NG, et al. (September 2007). "Sarcomatoid carcinoma of the lung: a predictor of poor prognosis". Ann. Thorac. Surg. 84 (3): 973–80. doi:10.1016/j.athoracsur.2007.03.099. PMID 17720411. <!- Page given was 981? ->
- Park JS, Lee Y, Han J, et al. (2011). "Clinicopathologic outcomes of curative resection for sarcomatoid carcinoma of the lung". Oncology. 81 (3-4): 206–13. doi:10.1159/000333095. PMID 22076573.
- Hellstrom HR, Fisher ER (1963). "Giant cell carcinoma of lung". Cancer. 16: 1080–8. doi:10.1002/1097-0142(196308)16:8<1080::aid-cncr2820160816>3.0.co;2-v. PMID 14050012.
- Kim TH, Kim SJ, Ryu YH, et al. (August 2004). "Pleomorphic carcinoma of lung: comparison of CT features and pathologic findings". Radiology. 232 (2): 554–9. doi:10.1148/radiol.2322031201. PMID 15215543.
- Zhao ZL, Song N, Huang QY, Liu YP, Zhao HR (February 2007). "[Clinicopathologic features of lung pleomorphic (spindle/giant cell) carcinoma—a report of 17 cases]" [Clinicopathologic features of lung pleomorphic (spindle/giant cell) carcinoma—a report of 17 cases]. Ai Zheng (in Chinese). 26 (2): 183–8. PMID 17298750. (Chinese text)
- Kallenberg F, Jaqué J (1979). "Giant cell carcinoma of the lung. Clinical and pathological assessment. Comparison with other large-cell anaplastic bronchogenic carcinomas.". Scand J Thorac Cardiovasc Surg. 13 (3): 343–6. doi:10.3109/14017437909100576. PMID 542838.
- Roggli VL, Vollmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R (1985). "Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases". Hum Pathol. 16: 569–79. doi:10.1016/s0046-8177(85)80106-4. PMID 2987102.
- Rossi G, Marchioni A, Sartori1 G, Longo L, Piccinini S, Cavazza A (2007). "Histotype in non-small-cell lung cancer therapy and staging: The emerging role of an old and underrated factor". Curr Resp Med Rev. 3: 69–77. doi:10.2174/157339807779941820.
- Vincent MD (2009). "Optimizing the management of advanced non-small-cell lung cancer: a personal view". Curr Oncol. 16: 9–21. doi:10.3747/co.v16i4.465. PMC . PMID 19672420.
- World Health Organization (1981). Histological typing of Lung Tumours (2nd ed.). Geneva: World Health Organization.
- Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (December 2001). "The new World Health Organization classification of lung tumours". Eur. Respir. J. 18 (6): 1059–68. doi:10.1183/09031936.01.00275301. PMID 11829087.
- Hiroshima K, Dosaka-Akita H, Usuda K, et al. (2011). "Cytological characteristics of pulmonary pleomorphic and giant-cell carcinomas". Acta Cytol. 55 (2): 173–9. doi:10.1159/000320860. PMID 21325803.
- Davidson JF, McNicol GP, Frank GL, Anderson TJ, Douglas AS (January 1969). "Plasminogen-activator-producing tumour". Br Med J. 1 (5636): 88–91. doi:10.1136/bmj.1.5636.88. PMC . PMID 5761832.
- Cacić M, Oberman B, Dvornik G (December 1989). "Investigation of the applicability of histological classification of bronchial carcinoma according to the World Health Organization". Tumori. 75 (6): 580–2. PMID 2482566.
- Matsui K, Kitagawa M (May 1991). "Spindle cell carcinoma of the lung. A clinicopathologic study of three cases". Cancer. 67 (9): 2361–7. doi:10.1002/1097-0142(19910501)67:9<2361::aid-cncr2820670925>3.0.co;2-3. PMID 1707339.
- Wang NS, Seemayer TA, Ahmed MN, Knaack J (January 1976). "Giant cell carcinoma of the lung. A light and electron microscopic study". Hum. Pathol. 7 (1): 3–16. doi:10.1016/s0046-8177(76)80003-2. PMID 172430.
- Naib ZM (1961). "Giant cell carcinoma of the lung: cytological study of the exfoliated cells in sputa and bronchial washings". Dis Chest. 40: 69–73. doi:10.1378/chest.40.1.69.
- Jiang DF, Lu YL, Qiu ZY, et al. (2003). "Study of differential expression of molecules affecting the metastatic potential between highly and poorly metastatic human lung giant cell carcinoma". Zhonghua Zhong Liu Za Zai. 25: 131–4.
- Kennedy A (May 1969). "Pathology and survival in operable cases of giant-cell carcinoma of the lung". J. Clin. Pathol. 22 (3): 354–60. doi:10.1136/jcp.22.3.354. PMC . PMID 5784984.
- Shirakusa T, Shigematsu N, Koga T, Yamagata Y (1980). "Giant cell carcinoma arising in a pulmonary bulla". Scand J Thorac Cardiovasc Surg. 14 (3): 307–9. doi:10.3109/14017438009101017. PMID 7221506.
- Hagihara N, Abe T, Wakamiya T, Sugita Y, Watanabe M, Tabuchi K (2010). "A case of brain metastasis from pulmonary giant cell carcinoma". Kurume Med J. 57 (1-2): 39–41. doi:10.2739/kurumemedj.57.39. PMID 21727764.
- Spivach A, Borea B, Bertoli G, Daris G (July 1976). "[Primary lung neoplasm of rare incidence: giant cell carcinoma]". Minerva Med. (in Italian). 67 (34): 2233–49. PMID 986035.
- Travis WD (November 2010). "Sarcomatoid neoplasms of the lung and pleura". Arch. Pathol. Lab. Med. 134 (11): 1645–58. doi:10.1043/2010-0086-RAR.1. PMID 21043818.
- Hayakawa K, Takahashi M, Sasaki K, Kawaoi A, Okano T (January 1977). "Primary choriocarcinoma of the lung: case report of two male subjects". Acta Pathol. Jpn. 27 (1): 123–35. PMID 557868.
- Willebrand H, Wernitsch W, Elmohamed A (September 1970). "[Pulmonary metastases of a giant-cell carcinoma in the bone—benign or malignant?]". Chirurg (in German). 41 (9): 419–23. PMID 5471024.
- Huang L, Xu J, Wood DJ, Zheng MH (March 2000). "Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation". Am. J. Pathol. 156 (3): 761–7. doi:10.1016/s0002-9440(10)64942-5. PMC . PMID 10702390.
- Werner M (December 2006). "Giant cell tumour of bone: morphological, biological and histogenetical aspects". Int Orthop. 30 (6): 484–9. doi:10.1007/s00264-006-0215-7. PMC . PMID 17013643.
- Pai SB, Lalitha RM, Prasad K, Rao SG, Harish K (September 2005). "Giant cell tumor of the temporal bone—a case report". BMC Ear Nose Throat Disord. 5: 8. doi:10.1186/1472-6815-5-8. PMC . PMID 16162299.
- Thomas C (1962). "[Giant cell carcinoma of the lungs]". Frankf Z Pathol (in German). 72: 302–8. PMID 13981042.
- Wellmann KF, Chafiian Y, Edelman E (February 1969). "Small bowel perforation from solitary metastasis of clinically undetected pulmonary giant cell carcinoma". Am. J. Gastroenterol. 51 (2): 145–50. PMID 5776147.
- Le Doussal JM, Gruaz-Guyon A, Martin M, Gautherot E, Delaage M, Barbet J (June 1990). "Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice". Cancer Res. 50 (11): 3445–52. PMID 2334941.
- Taya Y, Hosogai K, Hirohashi S, et al. (December 1984). "A novel combination of K-ras and myc amplification accompanied by point mutational activation of K-ras in a human lung cancer". EMBO J. 3 (12): 2943–6. PMC . PMID 6098458.
- Morgan AD, Mackenzie DH (January 1964). "Clear-cell Carcinoma of the Lung". J Pathol Bacteriol. 87: 25–7. doi:10.1002/path.1700870104. PMID 14106350.
- Carstens PH, Broghamer WL (April 1978). "Duodenal carcinoid with cytoplasmic whorls of microfilaments". J. Pathol. 124 (4): 235–8. doi:10.1002/path.1711240408. PMID 569192.
- Sidhu GS (July 1979). "The endodermal origin of digestive and respiratory tract APUD cells. Histopathologic evidence and a review of the literature". Am. J. Pathol. 96 (1): 5–20. PMC . PMID 37740.
- Culiner MM, Abouav J, Reich SB (November 1958). "Cavitary carcinoma of the lung". Calif Med. 89 (5): 355–8. PMC . PMID 13585165.
- Strang C, Simpson JA (March 1953). "Carcinomatous abscess of the lung". Thorax. 8 (1): 11–26. doi:10.1136/thx.8.1.11. PMC . PMID 13038734.
- Dailey JE, Marcuse PM (August 1969). "Gonadotropin secreting giant cell carcinoma of the lung". Cancer. 24 (2): 388–96. doi:10.1002/1097-0142(196908)24:2<388::aid-cncr2820240222>3.0.co;2-7. PMID 5796783.
- Yaturu S, Harrara E, Nopajaroonsri C, Singal R, Gill S (2003). "Gynecomastia attributable to a human chorionic gonadotropin-secreting giant cell carcinoma of the lung". Endocr Pract. 9 (3): 231–5. PMID 12917067.
- Kameda T; Kodama T; Shimosato Y (1982). Shimosato Y; Melamed MR; Nettesheim P, eds. Morphogenesis of Lung Cancer. 2. Boca Raton, Florida: CRC Press. pp. 107–29.
- Bae HM, Min HS, Lee SH, Kim DW, Chung DH, Lee JS, Kim YW, Heo DS (October 2007). "Palliative chemotherapy for pulmonary pleomorphic carcinoma". Lung Cancer. 58 (1): 112–5. doi:10.1016/j.lungcan.2007.05.006. PMID 17574296.
- Razzuk MA, Urschel HC, Albers JE, Martin JA, Paulson DL (June 1976). "Pulmonary giant cell carcinoma". Ann. Thorac. Surg. 21 (6): 540–5. doi:10.1016/s0003-4975(10)63926-4. PMID 1275605.
- Colby TV, Koss MN, Travis WD (1995). "Tumors of the lower respiratory tract". In Rosai J, Sobin LH. Atlas of Tumor Pathology. Washington DC: Armed Forces Institute of Pathology. pp. 259–75.
- Nash AD, Stout AP (1958). "Giant cell carcinoma of the lung; report of 5 cases". Cancer. 11: 369–76. doi:10.1002/1097-0142(195803/04)11:2<369::aid-cncr2820110222>3.0.co;2-8.
- Patton MM, McDonald JR, Moersch HJ (1951). "Bronchogenic large cell carcinoma". J Thorac Cardiovasc Surg. 22: 88.
- Walter JB, Pryce DM (June 1955). "The histology of lung cancer". Thorax. 10 (2): 107–16. doi:10.1136/thx.10.2.107. PMC . PMID 14396845.
- Hadley GG, Bullock WK (December 1953). "Autopsy reports of pulmonary carcinoma; survey in Los Angeles County Hospital for 1951". Calif Med. 79 (6): 431–3. PMC . PMID 13106728.
- Ozzello L, Stout AP (1961). "The epithelial origin of giant cell carcinoma of the lung confirmed by tissue culture. Report of a case". Cancer. 14: 1052–6. doi:10.1002/1097-0142(196109/10)14:5<1052::aid-cncr2820140521>3.0.co;2-d. PMID 13731858.
- Friedberg EC (February 1965). "Giant-Cell Carcinoma of the Lung: A dedifferentiated Adenocarcinoma". Cancer. 18: 259–64. doi:10.1002/1097-0142(196502)18:2<259::aid-cncr2820180219>3.0.co;2-f. PMID 14254083.
- "Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart". World Health Organization Classification of Tumours. (Download Page).
- "Lung cancer page". National Cancer Institute.